Creo Medical Group (CREO)

Sector:

Health Care

Index:

FTSE AIM All-Share

35.30p
   
  • Change Today:
      2.30p
  • 52 Week High: 48.10p
  • 52 Week Low: 23.25p
  • Currency: UK Pounds
  • Shares Issued: 361.48m
  • Volume: 1,320,816
  • Market Cap: £127.60m

Creo Medical buying freehold of current Chepstow headquarters

By Josh White

Date: Monday 14 Jun 2021

LONDON (ShareCast) - (Sharecast News) - Surgical endoscopy-focussed medical device company Creo Medical Group has exchanged contracts to acquire the freehold interest in the current site of its primary headquarters in Chepstow, Creo House, it announced on Monday.
The AIM-traded firm said it had also agreed to buy the adjacent site, for a total of £4.25m in cash, with the acquisition expected to complete in early July.

It said Creo House has a current total capacity of around 18,000 square feet and the adjacent site, subject to planning permission, would provide another 16,000 square feet of increased capacity.

That additional capacity would support Creo's commercial, operational and logistic footprint across Europe, following the acquisition of Albyn Medical in July and Boucart Medical in November, and would also provide additional manufacturing capacity for the commercial roll-out of the full range of products from the Creo gastrointestinal suite of advanced energy devices, which complement its 'Croma Advanced Energy Platform' and 'Speedboat' device for use in gastrointestinal therapeutic endoscopy.

The freehold was being acquired from Fastnet Property Investments, the site's original developer.

"We are delighted to have secured the freehold of Creo House as well as the adjacent site which, subject to planning permission, will provide increased capacity to support our commercial, operational and logistic footprint across Europe; as well as providing additional manufacturing capacity for the commercial roll-out of the full suite of advanced energy devices," said chief executive officer Craig Gulliford.

"By acquiring these sites, we are not only showing a firm commitment to Wales, but we are also giving our workforce even greater stability.

"The expansion is reflective of the rapid growth within Creo."

At 0807 BST, shares in Creo Medical Group were up 1.46% at 209p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CREO Market Data

Currency UK Pounds
Share Price 35.30p
Change Today 2.30p
% Change 6.97 %
52 Week High 48.10p
52 Week Low 23.25p
Volume 1,320,816
Shares Issued 361.48m
Market Cap £127.60m

CREO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
15.08% below the market average15.08% below the market average15.08% below the market average15.08% below the market average15.08% below the market average
25% below the sector average25% below the sector average25% below the sector average25% below the sector average25% below the sector average
Price Trend
13.95% above the market average13.95% above the market average13.95% above the market average13.95% above the market average13.95% above the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Income Not Available
Growth
15.86% below the market average15.86% below the market average15.86% below the market average15.86% below the market average15.86% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CREO Dividends

No dividends found

Trades for 17-May-2024

Time Volume / Share Price
17:07 37,500 @ 35.30p
16:35 305 @ 35.30p
16:35 305 @ 35.30p
16:28 29 @ 35.33p
16:20 3,539 @ 35.74p

CREO Key Personnel

CEO Craig Jonathan Gulliford
CFO Richard John Rees

Top of Page